Search - tctmd.com

Displaying 41 - 60 of 169

Sort: Relevancy | Date

LDL Cholesterol-Lowering Meds Rarely Intensified: GOULD

News Daily News

LDL Cholesterol-Lowering Meds Rarely Intensified: GOULD

Michael O'Riordan

June 18, 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

News Conference News EAS 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Michael O'Riordan

June 03, 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

News Conference News ACC 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Yael L. Maxwell

May 16, 2021

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

FDA Approves Evinacumab for Rare Homozygous FH

News Daily News

FDA Approves Evinacumab for Rare Homozygous FH

Michael O'Riordan

February 11, 2021

COVID-19: TCTMD’s Daily Dispatch for January

News Daily News

COVID-19: TCTMD’s Daily Dispatch for January

January 01, 2021

Inclisiran Approved in Europe for Lowering LDL Cholesterol

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

COVID-19: TCTMD’s Daily Dispatch for October

News Daily News

COVID-19: TCTMD’s Daily Dispatch for October

October 01, 2020

COVID-19: TCTMD’s Daily Dispatch for September

News Daily News

COVID-19: TCTMD’s Daily Dispatch for September

September 01, 2020

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

May 06, 2020

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

News Features

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

April 23, 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

Inclisiran Data in NEJM Prompt Talk of What Comes Next

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

March 24, 2020

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

Recurrent Events Common Among Young Patients With CAD

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.